CyberlinkASP Completes SSAE 16 SOC 1 Audit Across Datacenter Footprint

Company's facilities across Dallas, Chicago and London adhere to stringent security policies and procedures.

2013-03-12

DALLAS, TX, March 12, 2013 (Press-News.org) CyberlinkASP, the leader in hosted virtual desktop and private cloud solutions, today announced the completion of the company's annual SSAE 16 SOC 1 audit. CyberlinkASP enlisted an outside accounting firm and subjected itself to a rigorous third party review of all infrastructure, personnel, policies and procedures across its Dallas, Chicago and London facilities.

"This has been a major initiative for us the past few years as more and more firms require documented security policies and procedures relating to IT. We feel it's a must for anyone hosting or managing mission critical information technology," said Michael B. Sikorski, CIO of CyberlinkASP. This wide ranging SOC audit reviewed every aspect of CyberlinkASP's business, operations, security policies and executive oversight.

The Statement on Standards for Attestation Engagements (SSAE) No. 16 addresses a service organization's internal controls. Issued by the American Institute of Certified Public Accountants (AICPA), it is considered the authoritative guidance standard for service organizations. SSAE 16 was adopted by the American Institute of CPAs (AICPA) in an effort to establish a more uniform reporting standard.

About CyberlinkASP
CyberlinkASP is an information technology (IT) managed services firm providing: hosted virtual desktops, private cloud hosting, and security services. We currently operate datacenters in Dallas, Chicago and London. Our clients include financial institutions, health care providers, insurance companies, cargo logistics businesses, and payment card processors among others. Providing cloud solutions since 1999, CyberlinkASP operates from the U.S. and is privately owned. Please visit www.cyberlinkasp.com.

ELSE PRESS RELEASES FROM THIS DATE:

Laura Wellington: "The Four-Star Diet" Sells Out on Amazon Leading to Invitations From "All-Star" Talk Shows

2013-03-12

No doubt, the media tour for the author of "The Four-Star Diet: Based Upon The Wisdom Of General Colin Powell & Other Ridiculously Brilliant Leaders" has only just begun. Explosive sales on Amazon and similar retailers have made it nearly impossible to get your hands on a print version of the book. With the demand continuing to rise to an already "sell out" crowd, Author Laura J. Wellington has received invitations to appear on numerous "Celebrity, Style, and News" shows from as far away as the UAE. She will begin to make those appearances ...

Rush scientists identify buphenyl as a possible drug for Alzheimer's disease

2013-03-11

(CHICAGO) – Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer's disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood. Studies in mice with Alzheimer's disease (AD) have shown that sodium phenylbutyrate, known as Buphenyl, successfully increases factors for neuronal growth and protects learning and memory, according to neurological researchers at the Rush University Medical Center. Results from ...

Shock teams and ECMO save lives in massive STEMI

2013-03-11

MINNEAPOLIS, MN - March 9, 2013 - The use of extracorporeal membrane oxygenation (ECMO), accompanied by mechanical CPR, in patients with massive myocardial infarctions can lead to unexpected survival. These study findings are being presented March 9 at the American College of Cardiology Scientific Sessions. ECMO is an advanced technology that functions as a replacement for a critically ill patient's heart and lungs. This is the first report of combined ECMO, mechanical CPR and therapeutic hypothermia (TH) use within a STEMI Network. "For many patients who present with ...

Niacin therapy shows no benefits, has some harmful effects

2013-03-11

SAN FRANCISCO (March 9, 2013) — A highly anticipated study evaluating a combination of the vitamin niacin with the anti-flushing agent laropiprant finds the therapy provides no benefit to and may even be harmful for patients with vascular disease, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Detailed trial data is presented here for the first time. Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) is the largest-ever study of niacin, commonly used to raise ...

Drug protects against kidney injury from imaging dye in ACS patients

2013-03-11

SAN FRANCISCO (March 10, 2013) —High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. This group of patients is at high risk for kidney damage related to contrast agents used in imaging tests. Previous studies have demonstrated the kidney-protective value of various statins administered before patients undergo ...

Encouraging early results for redesigned Sapien valve

2013-03-11

SAN FRANCISCO (March 10, 2013) — The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study presented today at the American College of Cardiology's 62nd Annual Scientific Session. PARTNER II is the first randomized clinical trial involving the Sapien XT valve and the only one that compares the new device to the original FDA-approved Sapien ...

New biolimus stent equal to everolimus stent at 1 year

2013-03-11

SAN FRANCISCO (March 10, 2013) — In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today at the American College of Cardiology's 62nd Annual Scientific Session. Drug-eluting stents are structures placed inside narrowed coronary arteries to restore proper blood flow. A polymer coating on these devices slowly releases a drug designed to prevent restenosis—another blockage at the same site—and prevent a second ...

Fewer adverse events with 'double kissing' crush stent than culotte

2013-03-11

SAN FRANCISCO (March 10, 2013) — Patients with a type of coronary lesion linked with poor prognosis fared significantly better with the stent technique known as double kissing crush than with culotte stenting, according to data from the DKCRUSH-III trial presented today at the American College of Cardiology's 62nd Annual Scientific Session. DKCRUSH-III is the first head-to-head comparison of double kissing (DK) crush and culotte stent techniques in coronary artery disease. The study focused on bifurcation lesions, which involve a main branch and a smaller side branch ...

Cangrelor superior to clopidogrel in CHAMPION PHOENIX trial

2013-03-11

SAN FRANCISCO (March 10, 2013) — The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session. Cangrelor and clopidogrel interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting. Currently approved drugs in this class are effective in cutting down ischemic events—blood-flow reductions ...

New anti-clotting drug more effective than current treatment

2013-03-11

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine. Researchers report that the new drug, which is administered intravenously, reduced the odds of complications from stenting procedures. ...